Table 1.
Characteristics of the patients providing H/O vaccination and the subset from whom nasopharyngeal swabs were obtained.
| Parameter | Patients with H/O vaccination |
No of patients included in the study (NPS screened for viral RNA) |
p-Value |
|---|---|---|---|
| Total no of patients | 372 | 184 | |
| Males: Females | 215:157 | 104:80 | 0.77 |
| Age <50:>50 years | 210:162 | 106:78 | 0.79 |
| Comorbidities* | 113/367 (30.7%) | 63/177 (35.5 %) | 0.26 |
| Severe disease | 28/367 (7.6 %) | 27/177(15.2 %) | 0.009 |
| Moderate disease | 18/367 (4.9 %) | 16/177 (9 %) | 0.093 |
| Mild disease | 321/367 (87.4%) | 152/177 (85.8 %) | 0.61 |
| No of recipients (1 dose) | 200** | 90** | 0.96 |
| Covishield | 156 (78%) | 70 (77.7 %) | |
| Covaxin | 44 (22%) | 20 (22.2 %) | |
| No of recipients (2doses) | 103** | 52** | 0.43 |
| Covishield | 90 (87.3 %) | 43 (82.6 %) | |
| Covaxin | 13 (12.6 %) | 9 (17.3 %) |
*
Diabetes and hypertension either singly or in combination.
**
Information about the type of vaccine was available for 303.